Herbalife Q1 net sales $1.2B (down 3.4% YoY), adjusted EBITDA $164.9M beats guidance

HERBALIFE LTD.

2025-Q1 EPS reported $0.49 revenue$1,221,700,000

Net sales $1.2B at midpoint of guidance; down 3.4% YoY but up 1.4% on constant-currency basis.
Net income $50.4M; adjusted net income $59.9M; diluted EPS $0.49, adjusted diluted EPS $0.59.
Adjusted EBITDA $164.9M exceeds guidance; margin up 260 bps vs Q1 '24; leverage ratio reduced to 3.0x.
Full-year 2025 guidance revised: net sales range narrowed, adjusted EBITDA raised, capex reduced.
Completed acquisitions of Pro2col Health and Pruvit Ventures; formed HBL Link Bioscience with 51% ownership.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-25-037675
form_type: 8-K
ticker: HLF
cik: 0001180262
company_name: HERBALIFE LTD.
filed_at: 2025-04-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:47.717830+00:00
generated_at: 2026-05-23T02:01:16.440011+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-25-037675
json_url: https://secwatch.observer/filing/0001213900-25-037675.json
markdown_url: https://secwatch.observer/filing/0001213900-25-037675.md
text_url: https://secwatch.observer/filing/0001213900-25-037675.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1180262/000121390025037675/0001213900-25-037675-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1180262/000121390025037675/ea0240048-8k_herbalife.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001213900-25-037675

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.